Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger and Private Placement
12/23/24, 1:41 PM
Location
detroitMoney
$175 million
Type
agreement
Ikena Oncology, Inc. and Inmagene Biopharmaceuticals have entered into a definitive merger agreement, with a $75 million private placement to support further development of IMG-007, a monoclonal antibody targeting OX40 for the treatment of atopic dermatitis. The merger will result in approximately $175 million to support the development of IMG-007.
Company Info
Location
detroit, michigan, united states
Additional Info
UAB Kenton Baltic organizes conferences in Lithuania and Latvia, including the flagship business conference named EBIT and the popular conference named HR Week. These conferences bring together industry leaders and experts to share insights, discuss trends, and serve as a platform for professionals to exchange ideas, learn about the latest practices, and foster collaboration.